# A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

> **NCT01035502** · PHASE2 · COMPLETED · sponsor: **Clavis Pharma** · enrollment: 51 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Elacytarabine plus idarubicin

## Key facts

- **NCT ID:** NCT01035502
- **Lead sponsor:** Clavis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2013-09-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035502, "A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01035502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*